Prot #PQ-010-001: Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects with Homozygous ΔF508 Cystic Fibrosis

Project: Research project

StatusFinished
Effective start/end date3/1/163/1/19

Funding

  • INC Research, LLC (Prot #PQ-010-001)
  • ProQR Therapeutics III B.V. (Prot #PQ-010-001)